SELLAS Life Sciences shares plunge after $150 million offering
In short
SELLAS Life Sciences shares fell nearly 20% after the company priced a $150 million public offering at $13 a share. That was about 28% below its previous close.
What the reporting says
SELLAS Life Sciences shares plunged nearly 20% after the biotech company priced a $150 million public offering at $13 per share. The price was about 28% below the previous close, and the sell-off came after a sharp rally on positive Phase 3 REGAL trial results for its experimental leukemia vaccine. The move shows how dilution fears outweighed the earlier trial-driven gains.
Why it matters
SELLAS Life Sciences shares fell nearly 20% after the biotechnology company priced a $150 million public offering at $13 per share, about 28% below the previous close. The decline followed a prior rally tied to positive Phase 3 REGAL trial results for its experimental leukemia vaccine. The move is important for shareholders and the company's funding plans.